Research Literacy
What Does \"Research Use Only\" Actually Mean?
The short answer
Research Use Only is a labelling and marketing designation, not a safety or purity certification. It signals that a product has not gone through the regulatory process required to be marketed for human diagnostic or therapeutic use — nothing more. BPC-157, the most heavily marketed RUO peptide, has exactly one registered human trial in its history: a 2015 Phase 1 pharmacokinetic study (NCT02637284) that has sat at Unknown status for roughly a decade with no results ever posted. As of 2026, a small number of newly registered trials (BPC-157, TB-500, GHK-Cu) are testing these same molecules as real drug candidates for the first time — a regulatory pathway entirely separate from the vials sold online.
Quick answers
- What is it?
- "Research Use Only" (RUO) is a labelling category meaning a product hasn't completed the regulatory process required to be marketed for human use — it says nothing about safety, purity, or whether it works.
- Why are people interested in it?
- Peptides sold online carry this label while being marketed with dosing charts aimed squarely at people who intend to use them, so buyers need to know what the label actually does and doesn't guarantee.
- What has actually been studied?
- BPC-157's full ClinicalTrials.gov history — one completed 2015 Phase 1 safety trial in 42 healthy volunteers that never posted results — plus verification of a set of eight fabricated "Hudson Biotech" template trial records for BPC-157, TB-500, GHK-Cu, and other peptides.
- How strong is the evidence?
- Almost no legitimate human evidence exists behind the RUO peptide market: the real registered trial base is one small, unpublished Phase 1 study, and several records that appeared to show new human research were confirmed to be fictional templates, one of which admits this in its own summary.
- What don't we know yet?
- Whether any given RUO vial contains what its label claims, whether the newly registered 2026 trials will ever report results, and whether the tendon-, muscle-, and wound-healing signals seen in animal models will replicate in controlled human trials.
- Where can I read the original research?
- Sources at the bottom of this page: ClinicalTrials.gov, NCT02637284 (BPC-157 Phase 1 pilot study); and Mayfield CK, Bolia IK, Feingold CL, et al., The American Journal of Sports Medicine, 2026.
The short answer: "Research Use Only" (RUO) is a labelling and marketing designation, not a safety certification. It signals that a product hasn't completed the regulatory process required to market it for human diagnostic or therapeutic use — nothing about whether it works, is safe, or contains what the label claims. BPC-157, the most heavily marketed RUO peptide, has exactly one registered human trial in its history: a 2015 Phase 1 pharmacokinetic study that has sat at Unknown status on ClinicalTrials.gov for roughly a decade with no results made public. Meanwhile, a handful of newly registered 2026 trials are testing BPC-157, TB-500, and GHK-Cu as genuine drug candidates for the first time — a regulatory track entirely separate from the products sold as research chemicals.
What the research shows
What the label is actually for
"Research Use Only" originated as a category for laboratory reagents and diagnostic components — antibodies, assay kits, cell lines — sold to labs for developing or validating other tests, not for use on or in a patient. The label exists because regulators distinguish between a product marketed for human diagnostic or therapeutic use (which requires clearance, approval, or an active investigational pathway) and a product marketed for research purposes (which does not). The peptide market has borrowed this label wholesale: vials of BPC-157, TB-500, and similar compounds are now routinely sold online stamped "for laboratory research use only, not for human consumption," even when the surrounding marketing — dosing charts, injection guides, customer reviews — is unmistakably aimed at people who intend to inject them.
That matters because the label answers a narrow question — has this specific product been cleared for human use? — and that narrow answer gets read as a much broader one: has this compound been studied in humans, and is it safe? Those are different questions, and the label doesn't answer either.
The clearest case study: BPC-157's actual regulatory history
BPC-157 is a useful test case because its full clinical trial history is short enough to read in one sitting. A search of ClinicalTrials.gov turns up exactly three registered studies naming it as an intervention. The first, and to date the only completed one, is NCT02637284 — a Phase 1 pilot study sponsored by PharmaCotherapia d.o.o., testing an oral tablet formulation ("PCO-02," branded Bepecin) in 42 healthy volunteers at a single hospital site in Tijuana, Mexico. The trial ran from October 2015 through a completion date of March 2016, assessing safety and pharmacokinetics. Its listed status is Unknown — the record was never updated after its completion window passed — and no results have ever been posted for it.
For roughly a decade, that was the entire universe of registered human data on BPC-157 as an actual investigational drug. Everything else cited to support its use — tendon healing, gut protection, wound healing — comes from animal models, not from this trial or any other registered human study.
In February 2026 a set of records appeared that looked like exactly that change. One presented a Phase 2 trial of injectable BPC-157 for hamstring strain. Another presented a Phase 1/2 study of TB-500 in cardiovascular disease. A third presented a topical GHK-Cu wound study.
None of them are real studies.
Searching the registry by sponsor returns eight such records, all filed under the name Hudson Biotech, all listing a single site, and all but one carrying an identical primary-completion date of 14 February 2027. Between them they cover almost exactly the compounds with the heaviest online marketing:
| Record | Compound |
|---|---|
| NCT07437547 | BPC-157 |
| NCT07487363 | TB-500 |
| NCT07437586 | GHK-Cu |
| NCT07437560 | Melanotan II |
| NCT07505745 | MOTS-c |
| NCT07481734 | Tesamorelin |
| NCT07481747 | Tirzepatide |
| NCT07467447 | Retatrutide |
The TB-500 entry states in its own brief summary: "This fictional study is an example of a ClinicalTrials.gov-style record."
Two of the others are stranger still. NCT07481747 carries the exact title of SURMOUNT-1 — a genuine Eli Lilly tirzepatide trial — down to its enrolment figure of 2,539. NCT07467447 does something similar with a retatrutide study. The real trials exist, run by Eli Lilly, at hundreds of sites. These records copy their identity.
This is the practical lesson of the whole article. A registry listing is not evidence that research is happening. ClinicalTrials.gov is a self-submitted registry, not a vetted database — a sponsor writes the entry. A record can describe a plan, an abandoned intention, or a template. An NCT number proves a form was filled in, and nothing more.
So the honest position is unchanged: no controlled human trial has tested BPC-157 for tendon healing, none has tested TB-500 at all, and the only completed GHK-Cu human study was a 13-person cosmetic trial that found no objective benefit.
What the existing evidence actually looks like
A 2026 review in The American Journal of Sports Medicine, written by orthopaedic and sports medicine physicians at the Keck School of Medicine, surveyed the human and preclinical evidence behind the peptides most commonly sold under RUO labelling: BPC-157, TB-4/TB-500, CJC-1295 combined with ipamorelin, tesamorelin, and GHK-Cu. The conclusions were consistent across compounds. BPC-157's tendon- and muscle-repair effects are supported mainly by animal models; the one human case series the reviewers could find, involving intra-articular knee injections, carried "significant methodological flaws and a lack of controls." TB-4 and TB-500 showed tissue-repair signals in preclinical models, but the reviewers found no human orthopaedic data — and noted both remain banned substances under sports anti-doping rules regardless of marketing status. CJC-1295 combined with ipamorelin showed a positive effect on muscle tension in mice, but only in mice. The reviewers' overall judgment: dosing, frequency, duration, and safety all remain unknown for these compounds in human use, and "significant research... is required before definitive recommendations can be made to patients."
None of that is an argument that these compounds are dangerous. It's a statement about what has and hasn't been established — the gap an RUO label leaves open rather than closes.
Why the marketing context matters more than the sticker
A regulatory label is meant to travel with a product's actual, documented intended use. When a seller pairs "research use only" language with dosing calculators and testimonials about tendon pain or recovery, the sticker and the marketing tell two different stories — and the marketing describes how the product will actually be used. That mismatch is why the label can't do the work people expect: it was designed for lab reagents sold to institutions, not for what this market has become.
What we don't know yet
Whether any given RUO vial contains what its label claims. Independent, publicly reported purity or identity testing of research-chemical-market peptide products was not identified in this search. The registered trials above use pharmaceutical-grade formulations made under a specific protocol — a different supply chain from the consumer research-chemical market.
Whether the newly registered 2026 trials will report results at all. BPC-157's only prior completed trial never posted results and still shows Unknown status a decade later. Registering a new trial doesn't guarantee results will ultimately be published — a pattern explored further in Peptide Proof's companion piece on reading ClinicalTrials.gov.
Whether human efficacy will replicate the animal findings. Tendon-, muscle-, and wound-healing signals for these three peptides are well documented in rodent models. Whether they hold in controlled human trials — at what dose, for which injuries — is exactly what the new Hudson Biotech trials are designed to test, and the answer isn't in yet.
Sources
- ClinicalTrials.gov. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157. NCT02637284. Record
- ClinicalTrials.gov. NCT07437547 - template record presented as a BPC-157 hamstring trial; not a real study. Record
- ClinicalTrials.gov. NCT07487363 - self-identifies in its own summary as a fictional example record. Record
- ClinicalTrials.gov. NCT07437586 - template record presented as a GHK-Cu wound trial; not a real study. Record
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine, 2026;54(1):223-229. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Sources
- Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157
- ClinicalTrials.gov · NCT02637284, 2015 · n=42
- Template record presented as a BPC-157 hamstring trial - not a real study
- ClinicalTrials.gov / NCT07437547, 2026
- Template record presented as a TB-500 trial - self-identifies as fictional
- ClinicalTrials.gov / NCT07487363, 2026
- Template record presented as a GHK-Cu wound trial - not a real study
- ClinicalTrials.gov / NCT07437586, 2026
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- The American Journal of Sports Medicine, 2026 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.